Company: NIVFW
Filing Date: 2025-10-10
Form Type: F-1/A
Source: 0001213900-25-098135
Chunk: 186

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-10
Form: F-1/A
Chunk 186
---
 (ii) the fund-raising
activity by the Company from public or private shareholders, and in a form mutually acceptable to the parties, including structured equity
investment for up to US$ million. On December 11, 2024, NewGenIvf announced its entry into a binding term sheet with European Wellness
Investment Holdings Limited (“EWIHL”) for the above proposed reverse merger, completion of which was subject to, among other
conditions, the completion of due diligence, the negotiation of a definitive agreement, and obtaining adequate financing.

On May 24, 2024, the Company
received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying
the Company of its non-compliance with two (2) listing requirements for continued listing on Nasdaq pursuant to Nasdaq Listing Rules.
On November 21, 2024, a delisting notice was received from the continued non-compliance. The Company had filed to appeal the delisting
determination and undertook several strategic actions to regain compliance with Nasdaq’s listing require. On February 27, 2025.
received approval for the transfer the Company’s securities from the Nasdaq Global Market to the Nasdaq Capital Market and on March
10, 2025 its compliance with the listing requirements thereof.

On June 3, 2024, the Company
announced the execution of a non-binding term sheet (the “Term Sheet”) regarding a proposed reverse merger (the “Proposed
Transaction”) with pharmaceutical company COVIRIX Medical Pty Ltd (“COVIRIX”). The consideration was to be settled by
way of the issuance of (pre Reverse Stock Splits) of its ordinary shares to the shareholder(s) of COVIRIX or their respective
nominees (the “COVIRIX Shareholders”) in exchange for % equity interest of COVIRIX, at a deemed price per share of US$,
representing an aggregate amount of US$. Simultaneously, it is proposed that COVIRIX undertakes to introduce investors to raise
US$ million at US$ per share for NIVF, in a form mutually acceptable to both NewGen and COVIRIX. Following stockholder approval of the
Proposed Transaction, COVIRIX Shareholders are expected to hold approximately % equity interest in NewGen. However, on September 21,
2024, COVIRIX withdrew from the Proposed Transaction, as such the Proposed Transaction was